Better therapies for patients

We make a difference in people´s health - and in your portfolio

Grow your brand with added value for patients!

Whether it´s fewer side effects, a better API absorption or a personalized drug dispensing device, we at AET believe that there are always new ways of smart medicines which better deliver on patients´ needs. Our highly experienced research & development and innovation managers continuously strive for new pharmaceutical technologies and products – both in the field of generics and innovative formulations. This pioneer spirit is driven by our curiosity – the curiosity of each of our employees dedicated to make patients´ life better. To better understand patients´ needs, our experts are in close and regular collaboration with universities and key opinion leaders of all relevant disciplines.
Our own laboratories with up-to-date technologies and our exclusive global network of development partners enable us to cover all major therapeutics as well as diverse and innovative dosage forms. We succeed in developing tablets, capsules, modified release formulations, oral and ophthalmic solutions as well as special technologies like patches, inhalers, injectables or personalized devices. Our current portfolio consists of 180 products: 100 dossiers, 40 products under development and 40 in our pipeline. Every year, we start the development of 10 to 15 promising new products – both niche products and blockbusters – to fuel our sustainable growth. Outstanding intellectual property guidance and quality assurance are the backbone of our research & development operations.

How we drive better therapies for patients

Our success factors for breakthrough research and development

pioneer spirit and patient-focused development approach

close collaborations with universities and key opinion leaders of several indications

more than 100 products successfully developed

40 products under development and 40 in pipeline

pioneer spirit and patient focused development approach

close collaborations with universities and key opinion leaders of several indications

more than 100 products successfully developed

40 products under development and 40 in pipeline

special technologies and outstanding quality assurance

global IP clearance, protection, and filing

above-average success in BE and clinical studies

FDA, MIT and BGV approved own laboratories

special technologies and outstanding quality assurance

global IP clearance, protection, and filing

above-average success in BE and clinical studies

FDA, MIT and BGV approved own laboratories

Creating better therapies

Product examples of our ongoing development projects

Differentiated Products

Innovative Products

  • Once-daily products for better posology
  • More patient-friendly dosage forms than the innovator
  • Prodrugs with better side-effect profile (e.g. to make MS therapy safer)
  • Prodrug with 5 years of IP advantage
  • Extended-release formulations with less side effects
  • New suitable dosage strengths for better treatment options
  • Fix-dose combinations
  • Digital platform for new drug /device combination for personalized treatment
  • New orphan indication for known molecule
  • New OTC products
  • First NCE-approved drug in Europe

Differentiated Products

  • Once-daily products for better posology
  • More patient-friendly dosage form than the innovator
  • Prodrugs with better side-effect profile (e.g. to make MS therapy safer)
  • Prodrug with 5 years of IP advantage
  • Extended-release formulations with less side effects
  • New suitable dosage strengths for better treatment options
  • Fix-dose combinations

Innovative Products

  • Innovative vaginitis product
  • Digital platform for new drug /device combination for personalized treatment
  • New orphan indication for known molecule
  • New OTC products
  • First NCE approved drug in Europe

AET Laboratories - With advanced technologies to pharmaceuticals of the future

Our FDA approved laboratories in India

The Research and Development operations for both generic and innovative formulations are supported by our advanced laboratory in Hyderabad, India. AET Labs features a GLP/GMP-compliant environment on a 32.000 m² sized plant. Most modern techniques and softwares like an inhouse XRD Crystallography and WinNonlin IVIVC simulation tools are part of the state-of-the-art R&D equipment. Quality control is an integral part of AET Labs ensuring a development process which considers all aspects of quality requirements, customer requirements, transparency, and applying Good Manufacturing Practice according to national as well as international legislation. The development projects are performed following ICH, EU, USFDA and other international guidelines to generate a corresponding documentation for the submission of a marketing authorization application in the EU, in the US and further international territories. AET Labs holds the ISO 14001:2014 and ISO 18001:2015 certifications and was successfully inspected by the German BGV, the Russian MIT and US FDA authorities.

We are best practice

First NCE approval for innovative sleeping medicine

In 2019 AET successfully gained the first European NCE approval for an advanced drug being used to treat the symptoms of insomnia in a better and safer way. Studies have shown that our sleeping aid has the following main advantages compared to other sedative drugs: Our product has a lower dosage and, based on available studies, can be used for a longer period of time. Other sleeping pills may only be used for a maximum of two weeks. The innovative drug has been studied in a variety of clinical settings involving primary insomnia and insomnia secondary to various chronic conditions such as rheumatoid arthritis, generalised anxiety disorder, and major depressive illness. The results across studies in adults are consistent and demonstrate shorter sleep latency, longer sleep time, and less wakening after the onset of sleep compared to placebo. Furthermore, the study program revealed that our sleeping medicine provides safety benefits resulting from lower morning serum levels.

The product will be launched in 2021 in several European countries. With this first marketing authorization, AET enables thousands of patients in Europe suffering from insomnia a better and safer therapy – sustainably improving their quality of life.

We are happy to help, get in touch

Do not hesitate to get in touch for more information about our better therapies. Our experts are always available to help.